Policy | February 09, 2024
Growth of Ayush sector is bound to happen: Kotecha
Ayush is expanding beyond wellness to therapeutic wellness
Ayush is expanding beyond wellness to therapeutic wellness
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
The company recently received CEP certificate approval for Losartan Potassium by EDQM
At least one recognised startup in every State and UT; spread across over 80% of districts
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Subscribe To Our Newsletter & Stay Updated
